news
New screening method identifies COVID-19 protein inhibitor
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
List view / Grid view
Small molecule
news
New study may improve enzyme replacement therapy for Pompe patients
Researchers have developed a new method that could make enzyme replacement therapy more efficient for Pompe disease treatment.
news
Scientists discover new clue for platelet activation to target thrombosis
Researchers have revealed a novel mechanism for platelet activation, suggesting a potential target for antithrombotic therapy.
news
Existing drug may improve immune response to leukaemia treatment
Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
news
Removal of RNA-binding protein improves leukaemia survival
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
whitepaper
Catalogue: Drug target reagents
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
webinar
Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
article
Under the microscope: Searching for optimised drugs: combining AI with human expertise
Applying artificial intelligence (AI) to small molecule drug discovery can provide a more rapid and cost‑effective route to discovering drug candidates. Here, Martin Redhead, Head of Quantitative Pharmacology at Exscientia, discusses the role of AI in drug discovery, the processes involved and how it can be used to address the…
news
Researchers develop first synthetic inhibitor of coagulation factor XII
A new FXII inhibitor has been developed that efficiently blocked coagulation in a thrombosis model without increasing the risk of bleeding.
news
SRI-37330 revealed as drug candidate for treatment of diabetes
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
article
Unlocking the power of machine learning for small molecule drug discovery
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
whitepaper
Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
webinar
Cell-based Surface Plasmon Resonance with AstraZeneca
4 June 2020 | By Biosensing Instrument
In this webinar, we will provide an overview of the technology with some application examples and also see a case study how AstraZeneca is exploring SPRM for studies on G-protein-coupled receptors (GPCR) in close collaboration with Biosensing Instrument.
news
Binding site of drug compound and tumour suppressor protein revealed
Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
news
Novel antiviral compound proposed as COVID-19 therapeutic
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.